Home » Stocks » Processa Pharmaceuticals

Processa Pharmaceuticals, Inc. (PCSA)

Stock Price: $8.50 USD 0.00 (0.00%)
Updated Jul 22, 2020 4:00 PM EDT - End of day

Stock Price Chart

Key Info

Market Cap 46.88M
Revenue (ttm) n/a
Net Income (ttm) -3.25M
Shares Out 5.52M
EPS (ttm) -0.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 22, 2020
Last Price $8.50
Previous Close $8.50
Change ($) 0.00
Change (%) 0.00%
Day's Open 8.50
Day's Range 8.50 - 8.50
Day's Volume 200
52-Week Range 6.00 - 21.00

More Stats

Market Cap 46.88M
Enterprise Value 48.08M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 5.52M
Float 1.88M
EPS (basic) -0.64
EPS (diluted) -0.68
FCF / Share -0.48
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta -0.86
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 7.11
Revenue n/a
Operating Income -3.70M
Net Income -3.25M
Free Cash Flow -2.63M
Net Cash -1.20M
Net Cash / Share -0.22
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -21.70%
ROE -43.00%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$n/a*
*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue----0.110.110.310.19
Revenue Growth----5.77%-65.68%62.63%-
Gross Profit-----0.010.040.120.06
Operating Income-3.94-4.52-1.80-1.92-2.69-2.55-2.96-2.27
Net Income-3.36-3.77-1.86-1.92-3.35-4.53-3.07-2.44
Shares Outstanding5.535.334.664.190.220.180.100.04
Earnings Per Share-0.70-0.71-0.42-0.49-15.19-33.32-29.89-73.50
Operating Cash Flow-2.75-3.71-1.65-2.16-0.87-2.69-2.54-1.89
Capital Expenditures--0.02-0.02-0.020.03-0.01-0.03-0.33
Free Cash Flow-2.75-3.73-1.68-2.18-0.84-2.70-2.57-2.23
Cash & Equivalents0.691.742.852.090.000.000.191.02
Total Debt1.030.232.45-1.370.570.781.13
Net Cash / Debt-0.341.510.402.09-1.36-0.57-0.59-0.11
Assets10.8812.482.982.360.102.552.943.88
Liabilities2.872.782.610.102.081.341.271.32
Book Value8.019.700.372.27-1.981.211.672.56
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Processa Pharmaceuticals, Inc.
Country United States
Employees 13
CEO David Young

Stock Information

Ticker Symbol PCSA
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: PCSA

Description

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops drugs for the unmet medical needs in the United States. The company's lead product candidate is PCS-499, an oral tablet that is in Phase IIa clinical trial for the treatment of necrobiosis lipoidica, a chronic, disfiguring condition. It also has license agreement with Akashi Therapeutics, Inc. to develop and commercialize HT-100, an anti-fibrotic and anti-inflammatory drug. The company was formerly known as Heatwurx, Inc. and changed its name to Processa Pharmaceuticals, Inc. in October 2017. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.